

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|--|---|------------------|
| In re Application of |) | |
| |) | |
| R.C. Warrington, I.A. Paterson |) | Art Unit: |
| and A.A. Boulton |) | |
| |) | |
| Serial No. 09/600,125 |) | Examiner: |
| |) | |
| Filed: January 13, 1999 |) | |
| |) | |
| For: Composition Containing |) | |
| Propargylamine for Enhancing Cancer |) | |
| Therapy |) | |

The Commissioner of Patents
& Trademarks
Washington, D.C. 20231
U.S.A.

Dear Sir:

FILING OF AN INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicant hereby submits an Information Disclosure Statement on Form PTO-1449 containing a listing of patents and other publications of which Applicant is aware. Applicant is also submitting the references listed on the Information Disclosure Statement.

All of the patents and publications submitted herewith are in the English language. Accordingly a concise explanation of the relevance of the documents is not required.

The Examiner is requested to indicate consideration of these documents by initialling the appropriate column.


Applicants reserve the right to contest the applicability of any of these documents as prior art against the subject application. If the Examiner has any questions

concerning this Information Disclosure Statement, he/she is requested to contact the undersigned. Entry of the enclosed Information Disclosure Statement is believed to be in order and is respectfully requested.

This Information Disclosure Statement is being filed before the issuance of a first official action, and therefore no fees are required. However, please charge our deposit account No. 02-2095 if such a fee is required.

Respectfully submitted,

R.C. Warrington, I.A. Paterson, A.A. Boulton



Micheline Gravelle
Registration No. 40,261

Dated: July 10, 2001

Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario, Canada M5H 3Y2

(416) 364-7311